Actinium-225 FL 020 (Full-Life Technologies)

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameActinium-225 FL 020 (Full-Life Technologies)
Drug Alias Name[225Ac]Ac-FL-020225-Ac FL-020225Ac-FL-020
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionIonising radiation emittersProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesFull Life Technologies Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMinerva Imaging ApSFull Life Technologies LtdShanghai Full-life Technologies Co Ltd
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A